MVMD immediately proceeding with selection of Contract Research Organization to conduct adjuvant IPV study
Adjuvants are well known pharmacological or immunological agents that improve the immune response of a vaccine. Adjuvants are added to a vaccine to boost the immune response to produce more antibodies and longer-lasting immunity, thus minimizing the dose of antigen needed.
The Company's newly invented PANA process produces a stable nano-particulate adjuvant that does not agglomerate during repeated freeze-thaw cycles, avoiding negative effects on the vaccine strength, and requires only sterile filtration versus damaging high temperature autoclaving processes (sterilization method that uses high-pressure steam) associated with micro-particulate gel-based adjuvants.
Long standing aluminum adjuvants found in the marketplace today have proven dose-sparing characteristics with vaccines such as Inactivated Polio Vaccine ("IPV") but have numerous disadvantages in both manufacturing and stability, thus limiting their relative usefulness. The Company believes its patented PANA process overcomes the limitations of traditional aluminum-based adjuvants while significantly enhancing dose sparing stability and ease of use.
"It is a reasonable scientific objective that our new dose sparing adjuvant will enable us to deliver Inactivated Polio Vaccine with the same effect as a full standard dose that is used today, but using about 20 times less of the vaccine," stated
The Company has worked with its key vaccinology advisor, Dr. John Clements, PHD, Emeritus Professor of Microbiology and Immunology at
MVMD will be proceeding immediately with the selection of a Contract Research Organization to conduct an adjuvant IPV study that compares Alhydrogel adjuvant to the Company's stable nano-particulate adjuvant by both intermuscular injection and intradermal injection immunization, evaluating the antibody responses following vaccination with fractional doses of IPV comparing delivery types with IPV alone or adjuvanted.
"MVMD's newly developed stable nano-particulate adjuvant is a critical piece of our broader vaccine technology strategy and our current focus on completely eradicating Polio," stated
For more details on this release, please click on the following video interview:
https://www.youtube.com/watch?v=6bZ8qBwbNzA&feature=youtu.be
ABOUT
MVMD's proposition for delivering Quicksome™ formulations that have rapid onset, high bioavailability, low variability and precision dosing is core to the Company's success across key health and wellness categories. Consistent with its vision towards "Helping People Live Their Best Life", MVMD applies its Quicksome™ and Quicksol™ technologies to its ground-breaking work for advanced delivery of vaccines and pharmaceutical drugs as well as the development of products for pain management, weight loss, energy, focus, sleep, anxiety, and more.
The Company's patented Quicksome™ desiccation technology utilizes advanced liposomes and other stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats that are consumed orally. The result is a new generation of product formulations that are capable of delivering vaccines, drugs and nutraceuticals into the body faster, with greater impact, efficiency and accuracy. The Company's patented Quicksol™ solubilization technology covers all highly solubilized macrocyclic lactones (including the drugs Ivermectin and Selamectin). MVMD's solubility technology applied to the Ivermectin drug is the only form in the world that only uses excipients that are currently approved by the
For more Company information and contact details, visit www.mountainvalleymd.com.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
Certain statements contained in this news release may constitute forward-looking information. Forward-looking information is often, but not always, identified by the use of words such as "anticipate", "plan", "estimate", "expect", "may", "will", "intend", "should", and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information.
The Company's actual results could differ materially from those anticipated in this forward-looking information as a result of regulatory decisions, competitive factors in the industries in which the Company operates, prevailing economic conditions, and other factors, many of which are beyond the control of the Company.
The Company is making forward-looking statements, including but not limited to with respect to: the patentability and protection of the PANA process as well as its uses, applications and implications of use, including the effect on Polio, and related trials. The Company is not making any express or implied claims that the PANA process currently has the ability to eliminate, cure or eradicate Polio, or any other ailments or conditions, at this time.
The Company believes that the expectations reflected in the forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents the Company's expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.
SOURCE
© Canada Newswire, source